Peroxisome proliferator-activated receptor gamma: Promising target in glioblastoma
- Publication Type:
- Journal Article
- Citation:
- Panminerva Medica, 2018, 60 (3), pp. 109 - 116
- Issue Date:
- 2018-09-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| R41Y2018N03A0109.pdf | Published Version | 632.42 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2018 Edizioni Minerva Medica. Glioblastoma, also known as glioblastoma multiforme, is the most common and worldwide-spread cancer that begins within the brain. Glio-blastomas represent 15% of brain tumors. The most common length of survival following diagnosis is 12 to 14 months with less than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically 3 months. Among all receptors, special attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in glioblastoma. PPARs are ligand-activated intracellular transcription factors. The PPAR subfamily consists of three subtypes encoded by distinct genes named PPARa, PPARp/S, and PPARy. PPARy is the most extensively studied subtype of PPAR. There has been interesting preliminary evidence suggesting that diabetic patients receiving PPARy agonists, a group of anti-diabetics, thiazolidinedione drugs, have an increased median survival for glioblastoma. In this paper, the recent progresses in understanding the potential mechanism of PPARy in glioblastoma are summarized.
Please use this identifier to cite or link to this item: